Join and Earn Money FREE

Thursday, March 24, 2011

APCX- Now Current with Pinks!

Apptech Global is taking another step to prove to everyone that they mean business. Eric Ottens CEO has made APCX Current in the Pink sheets! Eric has been making leaps and bounds with Apptech Global. Expect a Press Release today updating its shareholders and future shareholders about APCX being Current and hopefully some more good news! Stay Tuned!!

I am expecting a Bullish pattern today! Keep your eyes on APCX!
I feel this is a perfect entry point for any new investor!!

APCX is O'Griffins Stock Pick of the Year!

All of this is my opinion.

UPDATED March 27, 2011- Turns out I was right on the money about the Press Release.
Press Release Below------

THE WOODLANDS, TexasMarch 24, 2011 /PRNewswire/ -- AppTech Corp announced today that it has achieved CURRENT STATUS designation on (Pinksheets). Eric Ottens, CEO of AppTech Corp commented: "We are pleased to report that we continue to meet our objectives for 2011 and this is a major step towards that goal and our vision to separate ourselves from other companies in the microcap market."

Tuesday, March 22, 2011

Stock update! APCX & EMLL

As for my stock picks for the week:

APCX- .0006

EMLL- .0009 Strongly feel you can quadruple your money in this stock at this price! Once they announce they have gold and it is being shipped! Check the recent PRs! I don't like to say this but BOOM! $$$$

AUCI- .0025 Trading on very small volume! Merger is still in the works!! When the PR comes it will make you some good money in my opinion!

Do some Due Diligence(DD) before investing in any penny stock!!

"Nothing Ventured, Nothing Gained"

See you all in the Bahamas Soon!

Monday, March 14, 2011

AppTech’s Oronoco Telecom Enters Into a Joint Venture Agreement With Conmudata of Colombia

Press Release Source: AppTech Corp On Monday March 14, 2011, 9:44 am EDT

THE WOODLANDS, Texas, March 14, 2011 /PRNewswire/ — AppTech Corp (Pink – News) is pleased to announce that its wholly owned subsidiary, Oronoco Telecom has entered into a Joint Venture with Conmudata of Colombia. Conmudata is a newly licensed operator and one of the few operators that have been granted interconnectivity to all major Colombian telecom networks.
With inbound traffic of more than 140 million minutes per month, Colombia is one of the major destinations for international voice traffic in Latin America.
Daniel Miroli, President of Oronoco states: “Oronoco has a great opportunity in this Joint Venture with Conmudata. Oronoco will handle all International inbound traffic going to Conmudata and expects to grow a substantial volume of sales. We anticipate that once we ramp up to full capacity, the revenue could exceed $200,000 per month.”  Eric Ottens, CEO of Apptech added: “Congratulations to Daniel who continues to deliver and surpass his sales projections.”
As part of the agreement Oronoco will also provide network diagramming and support, a Network Operation Center (NOC), monitoring and billing solutions as well as marketing support.
About AppTech Corp
AppTech Corp is developing mobile application market places serving emerging markets in Latin America, Brazil and the USA. AppTech is focused on multi-platform mobile apps designed to run on device operating systems such as Apple iPhone and Google’s Android.  In addition, through its wholly owned subsidiary, Oronoco Telecom, AppTech is working on securing agreements with top communication companies in Central America, South America and The Caribbean.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report.
Virmmac, LLC

I have already picked APCX as my stock pick of 2011! What do you think!? Have a GREEN DAY!!

Wednesday, March 9, 2011

Penny Stock Update- ILNS

  ILNS- Is currently trading at .0023x.0025. This stock is already in talk with Pfizer and other BIG Pharma companies! This new Vaccine is a HUGE BREAKTHROUGH!!  This company can easily take off, i would consider these prices cheap compared to what they can be if a buy-out was made. Even if this company doesn't get bought out, it has so much potential, with another Patent that should be announced within the next 90-120 days. This is absolutely a great historical find in my opinion. Clinical trials are already in progress for some of the drugs associated with ILNS. Here is a Press Release to help start off your Due Diligence.
LOS ANGELES, CA--(Marketwire - 07/14/10) - Intellect Neurosciences (OTC.BB:ILNS - News), a very small, publicly traded micro-cap company which was, until just recently, in debt and struggling to survive, is now in line for a chunk of the profits from the $20+ billion Alzheimer's Disease space.

A newly published report reveals for the first time how Pfizer, Wyeth, Elan, and Johnson and Johnson have all focused on attacking the illness by licensing and devloping a protected platform technology from Intellect Neurosciences.

"We believe that we have an approach that has the high potential to succeed because it targets a very primary point in Alzheimer's disease," said Dr. Daniel G. Chain Ph.D., Chairman and Chief Scientific Officer of ILNS. "We also believe that drugs which have the potential to slow down or arrest Alzheimer's disease are on the horizon now. We're much closer than we have been, previously."

Chain's father, Ernst Chain M.D. discovered how penicillin could be used as a dramatically effective, life-saving antibiotic. For his work, the elder Chain shared the Nobel Prize with the better-known Dr. Alexander Fleming and Chain's head of department, Howard Florey in the 1940s.

Now, some of the biggest pharmaceutical companies in the world may help Dr. Chain become known as the scientist who discovered what may prove to be not just a treatment for the symptoms -- but a way to stop or even prevent -- Alzheimer's disease.

"I'll never forget it -- the date was November 10, 1996," Chain explains. "I woke up on this unsuspecting Sunday morning with an idea for a potential therapy for Alzheimer's Disease. It just crystallized in my mind on that morning -- a way to prevent the accumulation of the toxin that floats in brain fluid."

Details about the sizable license agreements, which are scheduled to pay Intellect a mid-single digit royalty upon reaching certain milestones in the development and patent process, had never been published until now. Bound by non-disclosure agreements and strict corporate gag orders, not even Intellect Neurosciences has been allowed to publicly discuss key details of the agreements to their own investors.

"The company today has a very special value proposition," says Chain. "We have royalty bearing licenses. Some of the details are confidential but someone could potentially connect their own dots by looking closely through our filings with the SEC."

According to BioMedReports, as the company eliminated and converted their debt, they issued millions of new shares, but a vast majority of those shares are held by insiders who are subject to a one year lockup that expires on April 23, 2011 and prevents them from selling their shares.

According to the latest statistics, in America alone, 5.3 million people have Alzheimer's and those numbers are expected to double in the next thirty years.

Thus far, the U.S. Food and Drug Administration has approved only two types of medications for Alzheimer's and both only seek to treat the cognitive symptoms of the disease, not the disease itself.

Investors can find the full report and read details about these developments at BioMedReports.Com

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

Monday, March 7, 2011

Penny Stock Update! APCX!

APCX- is up from where i first posted it here from .0003 to .0016!! You can still get in on this stock as i have already averaged up and bought more at .0008 last week. This company is bringing in A LOT of revenue from Oronoco Telecommunications. More deals are being made as we speak in Argentina and Honduras. They are working really hard in gaining more clients in South America. Projected revenues are around $3,000,000 by years end from Oronoco, says Eric Ottens-CEO of Apptech Global.

 Another Press Release should be out giving us more updates and should keep the PPS going up!! In my opinion if you were to get in now at .0016 you can easily double your money this week alone! Thats my feel for APCX! More updates soon to come!